Hopkinton biotech's new parent company expands into mRNA
Photo | Grant Welker
LakePharma, a Hopkinton-based firm, was acquired by Curia.
Curia, a New York-based contract research and manufacturing organization formerly known as AMRI Global, has introduced mRNA technology to its production of cancer, heart disease, and vaccine treatments.
The December announcement of the move to mRNA technology, whose profile has risen with its use in COVID vaccines from Moderna and Pfizer, came after Curia acquired LakePharma Inc., which has offices in Hopkinton and Worcester, in September.
Through the acquisition of LakePharma, Curia will offer expertise in large and small molecules from drug discovery through drug substance manufacturing, sterile injectable formulation, and fill-finish production, per the release.
LakePharma will operate as part of Curia’s Research and Development division and its founder and CEO will serve on Curia’s executive team as its chief technology officer. The acquisition marks Curia’s expansion into California, Massachusetts, and Texas.
“The completion of LakePharma transforms our biologics offering, enabling us to provide end-to-end capabilities to customers, based on deep scientific expertise and an integrated technology platform,” said Curia Chairman and CEO John Ratliff, in the September press release.
WBJ Web Partners
Most Recent
Most Recent
0 Comments